Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. ...
예상 EPS $-0.20 · 매출 $6.85M · 3 명의 애널리스트
예상 EPS $-0.18 · 매출 $9.93M · 3 명의 애널리스트
예상 EPS $-0.82 · 매출 $25.27M · 3 명의 애널리스트
예상 EPS $-0.21 · 매출 $8.05M · 1 명의 애널리스트
EPS $-0.27 · 매출 $5.29M
EPS $-0.52 · 매출 $2.21M
EPS $-0.36 · 매출 $2.62M
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $16.4M | +61.1% | -52.8% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-43.3M | -63.6% | -37.2% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +70.8% | +7.4% | +9.2% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -256.3% | +17.2% | -196.5% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -264.4% | -1.5% | -190.7% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-39.1M | -66.5% | -32.1% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -238.4% | -3.4% | -180.0% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 7.1% | -16.3% | +16.1% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 12.52x | +19.1% | -1.5% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $192.9M | +174.7% | -15.4% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -1.43 vs -1.36 | -4.8% | -0.26 vs -0.20 | -26.9% |
| 매출 서프라이즈 | $16.4M vs $17.6M | -6.8% | $2.5M vs $6.8M | -63.8% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| May 16, 2025 | Menawat Arun Swarup | director, officer: CEO | Common Shares | A | 12,027 | $4.73 |
| May 15, 2025 | Menawat Arun Swarup | director, officer: CEO | Common Shares | A | 10,003 | $4.33 |
| Dec 20, 2012 | HOFER MICHAEL | director | Patriot Minefinders Inc. | D | 40,000 | $0.16 |
| Dec 18, 2012 | HOFER MICHAEL | director | Patriot Minefinders Inc. | D | 40,000 | $0.15 |
| Jun 19, 2012 | TEJADA FRED | director | Common Shares | A | 500,000 | $0.00 |
Operator: Good day, and thank you for standing by. Welcome to ProFound Medical's Second Quarter 26 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Stephen Kilmer, Investor Relations. Stephen Kilmer: Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward looking statements within the meaning of applicable securities laws in The United States and Canada. All forward looking statements are based on ProFound's current beliefs, assumptions and expectations, and relate to, among other things, any expressed or implied statements or guidance regarding current or future financial performance, and position and expectations regarding the efficacy of ProFound's technology. Such statements involve known and unknown risks and uncertainties. And other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these forward looking statements. Which speak only as of the date of this conference call. ProFound undertakes no obligation to publicly update or revise any forward looking statement whether as a result of new information, future events or otherwise, other than as required by law. Representing the company today are Arun Swarup Menawat, Co-Founder's Chief Executive Officer and Chairman Doctor. Mathieu Burtnyk, Profound's President and Tom Tamberrino, our Chief Commercial Officer. Also filling in for our CFO, Rashed due to a scheduling issue is our Corporate Controller, Matthew Sobczyk. With that said, I will now turn the call over to Arun. Arun Swarup Menawat: Good afternoon, everyone. And welcome to the second quarter 26 Conference Call. On behalf of the management team, and everyone at ProFound, I would like to thank you for your ongoing interest in our company. For those of you who are shareholders, we appreciate your continued interest and support. Matthew Sobczyk: I will turn the call over to Mathieu in a moment to provide clinical updates. However, before I do, I would like to provide a brief summary of our second quarter 26 financial results. All of the numbers I will refer to have been rounded. So they are approximate. For the 3 month period ended June 30, 2026, the company recorded revenue of $2.5 million with $1.6 million from recurring revenue and $871 thousand from capital equipment sales. Second quarter 26 revenue was up 12% from $2.2 million for the same 3 …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | CAD 998,593 | — | 1955 | Active |
Mathieu Burtnyk | President | CAD 479,836 | — | 1982 | Active |
Rashed Dewan | Chief Financial Officer | CAD 472,272 | Male | 1968 | Active |
Thomas Tamberrino | Chief Commercial Officer | CAD 382,200 | Male | 1980 | Active |
Matthew Sobczyk | Assistant Corporate Controller | — | Male | — | Active |
Stephen Kilmer | Investor Relations | — | Male | — | Active |
Levant Tinaz | Software Developer | — | Male | — | Active |
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company's Chief Financial Officer.
A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June.
Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.
